Asset acquisition (Additional Information) (Details) - Nova Pharmaceuticals, Inc. $ in Millions |
6 Months Ended |
|---|---|
|
Jun. 30, 2025
USD ($)
shares
| |
| Business Combination [Line Items] | |
| Business Combination, Consideration Transferred, Total | $ | $ 2.6 |
| Series B Preferred Stock [Member] | |
| Business Combination [Line Items] | |
| Stock Issued During Period, Shares, Acquisitions | shares | 119,318 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|